ATI-1777
ATI-1777-AD-201
Phase 2 small_molecule completed
Quick answer
ATI-1777 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed